{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:48:42Z","timestamp":1784252922470,"version":"3.55.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10549-018-4996-3","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T06:05:11Z","timestamp":1542866711000},"page":"15-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies"],"prefix":"10.1007","volume":"174","author":[{"given":"Raquel N.","family":"Rozner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azael","family":"Freites-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza B.","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"key":"4996_CR1","unstructured":"World Health Organization. WHO | breast cancer: prevention and control. http:\/\/www.who.int\/cancer\/detection\/breastcancer\/en\/ . Accessed 26 Nov 2017"},{"issue":"1","key":"4996_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics (2018) CA Cancer J Clin 2018 68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin 2018"},{"issue":"5","key":"4996_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5301\/tj.5000376","volume":"101","author":"L Moscetti","year":"2015","unstructured":"Moscetti L, Agnese Fabbri M, Sperduti I et al (2015) Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 101(5):469. https:\/\/doi.org\/10.5301\/tj.5000376","journal-title":"Tumori"},{"issue":"10","key":"4996_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Wu S, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126\u20131134. https:\/\/doi.org\/10.1634\/theoncologist.2013-0193 . Epub 13 Sep 2013","journal-title":"Oncologist"},{"key":"4996_CR5","doi-asserted-by":"publisher","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431\u20132442. https:\/\/doi.org\/10.1056\/NEJMra023246 . Accessed 6 April 2018","DOI":"10.1056\/NEJMra023246"},{"key":"4996_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.056","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, van den Hurk C, et al (2018) CME part 2: hair disorders in cancer survivors persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.056","journal-title":"J Am Acad Dermatol"},{"key":"4996_CR7","doi-asserted-by":"publisher","unstructured":"Freites-Martinez A, Shapiro J, Chan D et al (2018) Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0454","DOI":"10.1001\/jamadermatol.2018.0454"},{"key":"4996_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/annonc\/mdq087","volume":"21","author":"H Bourgeois","year":"2010","unstructured":"Bourgeois H, Kerbrat P, Combe M et al (2010) Long term persistent alopecia and suboptimal hair regrowth after adjuvant chemotherapy for breast cancer: alert for an emerging side effect: French ALOPERS Observatory. Ann Oncol 21:83\u201384","journal-title":"Ann Oncol"},{"key":"4996_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/annonc\/mdx224","volume":"28","author":"D Kang","year":"2017","unstructured":"Kang D, Kim IR, Lee D et al (2017) Incidence of permanent chemotherapy-induced alopecia among breast cancer patients: a five-year prospective cohort study. Ann Oncol 28:22","journal-title":"Ann Oncol"},{"key":"4996_CR10","doi-asserted-by":"publisher","unstructured":"Kim S, Park H, Kim J et al (2016) Irreversible chemotherapy-induced alopecia in breast cancer patient. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS15-P1-15-04","DOI":"10.1158\/1538-7445.SABCS15-P1-15-04"},{"issue":"1","key":"4996_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1188\/09.CJON.13-14","volume":"13","author":"P Masidonski","year":"2009","unstructured":"Masidonski P (2009) Permanent alopecia in women being treated for breast cancer. Clin J Oncol Nurs 13(1):13\u201315. https:\/\/doi.org\/10.1188\/09.CJON.13-14","journal-title":"Clin J Oncol Nurs"},{"key":"4996_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS13-P3-09-15","author":"M Bertrand","year":"2013","unstructured":"Bertrand M, Mailliez A, Vercambre S, Kotecki N, Mortier L, Bonneterre J(2013) Permanent chemotherapy induced alopecia in early breast cancer patients after (neo)adjuvant chemotherapy: long term follow up. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.SABCS13-P3-09-15","journal-title":"Cancer Res"},{"issue":"5","key":"4996_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaad.2016.12.027","volume":"76","author":"A Fonia","year":"2017","unstructured":"Fonia A, Cota C, Setterfield JF, Goldberg LJ, Fenton DA, Stefanato CM (2017) Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol 76(5):948\u2013957. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.027","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4996_CR14","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/annonc\/mds095","volume":"23","author":"N Kluger","year":"2012","unstructured":"Kluger N, Jacot W, Frouin E et al (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879\u20132884. https:\/\/doi.org\/10.1093\/annonc\/mds095 . Epub 9 May 2012","journal-title":"Ann Oncol"},{"key":"4996_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS14-P5-17-04","author":"N Thorp","year":"2015","unstructured":"Thorp N, Swift F, Arundell D, Wong H (2015) Long term hair loss in patients with early breast cancer receiving docetaxel chemotherapy. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS14-P5-17-04","journal-title":"Cancer Res"},{"key":"4996_CR16","unstructured":"Otberg N, Shapiro J (2012) Chapter 88. Hair growth disorders. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (eds) Fitzpatrick\u2019s dermatology in general medicine, 8th edn. The McGraw-Hill Companies, New York. http:\/\/accessmedicine.mhmedical.com\/content.aspx?aid=56049509 . Accessed 25 March 2018"},{"issue":"3","key":"4996_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","volume":"152","author":"R Sinclair","year":"2005","unstructured":"Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152(3):466\u2013473. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06218.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"4996_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jamadermatol.2016.5790","volume":"153","author":"EJ Zuuren van","year":"2017","unstructured":"van Zuuren EJ, Fedorowicz Z (2017) Interventions for female pattern hair loss. JAMA Dermatol 153(3):329\u2013330. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5790","journal-title":"JAMA Dermatol"},{"key":"4996_CR19","doi-asserted-by":"publisher","unstructured":"Clinical efficacy of oral administration of finasteride at a dose of 2.5\u00a0mg\/day in women with female pattern hair loss (2018). Dermatol Ther 31(2):e12588. https:\/\/doi.org\/10.1111\/dth.12588","DOI":"10.1111\/dth.12588"},{"issue":"1","key":"4996_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sder.2009.01.001","volume":"28","author":"F Camacho-Martinez","year":"2009","unstructured":"Camacho-Martinez F (2009) Hair loss in women. Semin Cutan Med Surg 28(1):19\u201332. https:\/\/doi.org\/10.1016\/j.sder.2009.01.001","journal-title":"Semin Cutan Med Surg"},{"key":"4996_CR21","doi-asserted-by":"publisher","unstructured":"Tr\u00fceb RM (2004) Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 209(3):202\u2013207. https:\/\/doi.org\/10.1159\/000079890 . Accessed 20 March 2018","DOI":"10.1159\/000079890"},{"issue":"4","key":"4996_CR22","first-page":"414","volume":"15","author":"LR Seale","year":"2016","unstructured":"Seale LR, Eglini AN, McMichael AJ (2016) Side effects related to 5 \u03b1-reductase inhibitor treatment of hair loss in women: a review. J Drugs Dermatol 15(4):414\u2013419","journal-title":"J Drugs Dermatol"},{"key":"4996_CR23","doi-asserted-by":"publisher","unstructured":"Gupta AK, Charrette A (2014) The efficacy and safety of 5\u03b1-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatol Treat 25(2):156\u2013161. https:\/\/doi.org\/10.3109\/09546634.2013.813011 . Accessed 26 March 2018","DOI":"10.3109\/09546634.2013.813011"},{"issue":"2","key":"4996_CR24","first-page":"73","volume":"90","author":"O Boychenko","year":"2012","unstructured":"Boychenko O, Bernstein RM, Schweiger ES (2012) Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. Cutis 90(2):73\u201376","journal-title":"Cutis"},{"key":"4996_CR25","doi-asserted-by":"publisher","unstructured":"Yeon JH, Jung JY, Choi JW et al (2011) 5\u00a0mg\/day finasteride treatment for normoandrogenic asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 25(2):211\u2013214. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03758.x . Accessed 26 March 2018","DOI":"10.1111\/j.1468-3083.2010.03758.x"},{"key":"4996_CR26","doi-asserted-by":"publisher","unstructured":"Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G (2010) Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 146(10):1141\u20131150. https:\/\/doi.org\/10.1001\/archdermatol.2010.256 . Accessed 26 March 2018","DOI":"10.1001\/archdermatol.2010.256"},{"key":"4996_CR27","doi-asserted-by":"publisher","unstructured":"Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A (2006) Finasteride treatment of female pattern hair loss. Arch Dermatol 142(3):298\u2013302. https:\/\/doi.org\/10.1001\/archderm.142.3.298 . Accessed 26 March 2018","DOI":"10.1001\/archderm.142.3.298"},{"key":"4996_CR28","doi-asserted-by":"publisher","unstructured":"Price VH, Roberts JL, Hordinsky M et al (2000) Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 43(5 Pt 1):768\u2013776. https:\/\/doi.org\/10.1067\/mjd.2000.107953 . Accessed 20 March 2018","DOI":"10.1067\/mjd.2000.107953"},{"key":"4996_CR29","doi-asserted-by":"publisher","unstructured":"Moghetti P, Castello R, Magnani CM et al (1994) Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab 79(4):1115\u20131121. https:\/\/doi.org\/10.1210\/jcem.79.4.7962284 . Accessed 11 April 2018","DOI":"10.1210\/jcem.79.4.7962284"},{"issue":"1","key":"4996_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1210\/jcem.80.1.7829618","volume":"80","author":"IL Wong","year":"1995","unstructured":"Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA (1995) A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 80(1):233\u2013238. https:\/\/doi.org\/10.1210\/jcem.80.1.7829618","journal-title":"J Clin Endocrinol Metab"},{"key":"4996_CR31","unstructured":"Castello R, Tosi F, Perrone F, Negri C, Muggeo M, Moghetti P (1996) Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 66(5):734\u2013740. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8893676"},{"issue":"4","key":"4996_CR32","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1210\/jcem.84.4.5591","volume":"84","author":"S Venturoli","year":"1999","unstructured":"Venturoli S, Marescalchi O, Colombo FM et al (1999) A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 84(4):1304\u20131310. https:\/\/doi.org\/10.1210\/jcem.84.4.5591","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4996_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1067\/mjd.2002.124608","volume":"47","author":"KW Shum","year":"2002","unstructured":"Shum KW, Cullen DR, Messenger AG (2002) Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 47(5):733\u2013739","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4996_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-014-0078-4","volume":"15","author":"N Somani","year":"2014","unstructured":"Somani N (2014) Hirsutism: an evidence-based treatment update. Am J Clin Dermatol 15(3):247\u2013267. https:\/\/doi.org\/10.1007\/s40257-014-0078-4","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"4996_CR35","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/annonc\/mdt170","volume":"24","author":"A Rossi","year":"2013","unstructured":"Rossi A, Iorio A, Scali E et al (2013) Aromatase inhibitors induce \u2018male pattern hair loss\u2019 in women? Ann Oncol Off J Eur Soc Med Oncol 24(6):1710. https:\/\/doi.org\/10.1093\/annonc\/mdt170","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"4996_CR36","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1001\/archderm.1975.01630230098020","volume":"111","author":"VH Price","year":"1975","unstructured":"Price VH (1975) Testosterone metabolism in the skin. A review of its function in androgenetic alopecia, acne vulgaris, and idiopathic hirsutism including recent studies with antiandrogens. Arch Dermatol 111(11):1496\u20131502","journal-title":"Arch Dermatol"},{"issue":"4","key":"4996_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0733-8635(05)70396-X","volume":"14","author":"KD Kaufman","year":"1996","unstructured":"Kaufman KD (1996) Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 14(4):697\u2013711","journal-title":"Dermatol Clin"},{"key":"4996_CR38","doi-asserted-by":"publisher","unstructured":"Price VH (1999) Treatment of hair loss. N Engl J Med 341(13):964\u2013973. https:\/\/doi.org\/10.1056\/NEJM199909233411307 . Accessed 19 March 2018","DOI":"10.1056\/NEJM199909233411307"},{"issue":"12","key":"4996_CR39","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s004030000184","volume":"292","author":"P Vexiau","year":"2000","unstructured":"Vexiau P, Chaspoux C, Boudou P et al (2000) Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res 292(12):598\u2013604","journal-title":"Arch Dermatol Res"},{"key":"4996_CR40","doi-asserted-by":"publisher","unstructured":"Ohnemus U, Uenalan M, Inzunza J, Gustafsson J, Paus R (2006) The hair follicle as an estrogen target and source. Endocr Rev 27(6):677\u2013706. https:\/\/doi.org\/10.1210\/er.2006-0020 . Accessed 31 May 2018","DOI":"10.1210\/er.2006-0020"},{"key":"4996_CR41","doi-asserted-by":"publisher","unstructured":"Conrad F, Ohnemus U, Bodo E et al (2005) Substantial sex-dependent differences in the response of human scalp hair follicles to estrogen stimulation in vitro advocate gender-tailored management of female versus male pattern balding. J Investig Dermatol Symp Proc 10(3):243\u2013246. https:\/\/doi.org\/10.1111\/j.1087-0024.2005.10115.x .Accessed 31 May 2018","DOI":"10.1111\/j.1087-0024.2005.10115.x"},{"key":"4996_CR42","doi-asserted-by":"publisher","unstructured":"Langan EA, Paus R (2010) Female pattern hair loss: beyond an androgenic aetiology? Br J Dermatol 163(5):1142. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09955.x . Accessed 31 May 2018","DOI":"10.1111\/j.1365-2133.2010.09955.x"},{"key":"4996_CR43","doi-asserted-by":"publisher","unstructured":"Bickenbach KA, Jaskowiak N (2006) Aromatase inhibitors: an overview for surgeons. J Am Coll Surg 203(3):376\u2013389. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2006.05.291 . Accessed 19 March 2018","DOI":"10.1016\/j.jamcollsurg.2006.05.291"},{"key":"4996_CR44","doi-asserted-by":"publisher","unstructured":"Yu H, Shu X, Shi R et al (2003) Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer 105(1):92\u201397. https:\/\/doi.org\/10.1002\/ijc.11034 . Accessed 19 March 2018","DOI":"10.1002\/ijc.11034"},{"issue":"5","key":"4996_CR45","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ctrv.2011.08.003","volume":"38","author":"M Re Del","year":"2012","unstructured":"Del Re M, Michelucci A, Simi P, Danesi R (2012) Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat Rev 38(5):442\u2013450. https:\/\/doi.org\/10.1016\/j.ctrv.2011.08.003","journal-title":"Cancer Treat Rev"},{"issue":"10-11","key":"4996_CR46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/0020-711X(94)90091-4","volume":"26","author":"JA Boutin","year":"1994","unstructured":"Boutin JA (1994) Tyrosine protein kinase inhibition and cancer. Int J Biochem 26(10\u201311):1203\u20131226","journal-title":"Int J Biochem"},{"key":"4996_CR47","doi-asserted-by":"publisher","unstructured":"Fortunati N (1999) Sex hormone-binding globulin: not only a transport protein. What news is around the corner? J Endocrinol Investig 22(3):223\u2013234. https:\/\/doi.org\/10.1007\/BF03343547 . Accessed 19 March 2018","DOI":"10.1007\/BF03343547"},{"key":"4996_CR48","doi-asserted-by":"publisher","unstructured":"Yip L, Zaloumis S, Irwin D et al (2009) Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 161(2):289\u2013294. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09186.x . Accessed 20 March 2018","DOI":"10.1111\/j.1365-2133.2009.09186.x"},{"key":"4996_CR49","doi-asserted-by":"publisher","unstructured":"Yip L, Rufaut N, Sinclair R (2011) Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 52(2):81\u201388. https:\/\/doi.org\/10.1111\/j.1440-0960.2011.00745.x . Accessed 20 March 2018","DOI":"10.1111\/j.1440-0960.2011.00745.x"},{"key":"4996_CR50","doi-asserted-by":"publisher","unstructured":"Mirmirani P (2011) Hormonal changes in menopause: do they contribute to a \u2018midlife hair crisis\u2019 in women? Br J Dermatol 165(Suppl 3):7\u201311. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10629.x . Accessed 20 March 2018","DOI":"10.1111\/j.1365-2133.2011.10629.x"},{"key":"4996_CR51","doi-asserted-by":"publisher","unstructured":"Neven P, Paridaens R, Pelgrims G et al (2008) Fulvestrant (faslodex) in advanced breast cancer: clinical experience from a Belgian Cooperative Study. Breast Cancer Res Treat 109(1):59\u201365. https:\/\/doi.org\/10.1007\/s10549-007-9628-2 . Accessed 19 March 2018","DOI":"10.1007\/s10549-007-9628-2"},{"key":"4996_CR52","doi-asserted-by":"publisher","unstructured":"Atanaskova Mesinkovska N, Bergfeld WF (2013) Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin 31(1):119\u2013127. https:\/\/doi.org\/10.1016\/j.det.2012.08.005 . Accessed 20 March 2018","DOI":"10.1016\/j.det.2012.08.005"},{"key":"4996_CR53","doi-asserted-by":"publisher","unstructured":"Gallicchio L, Calhoun C, Helzlsouer KJ (2013) Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat 142(2):435\u2013443. https:\/\/doi.org\/10.1007\/s10549-013-2744-2 . Accessed 19 March 2018","DOI":"10.1007\/s10549-013-2744-2"},{"issue":"5 Pt 1","key":"4996_CR54","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0190-9622(88)70241-8","volume":"19","author":"W Futterweit","year":"1988","unstructured":"Futterweit W, Dunaif A, Yeh HC, Kingsley P (1988) The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 19(5 Pt 1):831\u2013836","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4996_CR55","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1210\/jcem.79.3.8077369","volume":"79","author":"F Fruzzetti","year":"1994","unstructured":"Fruzzetti F, de Lorenzo D, Parrini D, Ricci C (1994) Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab 79(3):831\u2013835. https:\/\/doi.org\/10.1210\/jcem.79.3.8077369","journal-title":"J Clin Endocrinol Metab"},{"key":"4996_CR56","unstructured":"Ciotta L, Cianci A, Calogero AE et al (1995) Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 64(2):299\u2013306. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7615107"},{"key":"4996_CR57","unstructured":"Bayhan G, Bahceci M, Demirkol T, Ertem M, Yalinkaya A, Erden AC (2000) A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. Clin Exp Obstet Gynecol 27(3\u20134):203\u2013206. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11214952"},{"key":"4996_CR58","unstructured":"Bayram F, Muderris II, Guven M, Kelestimur F (2002) Comparison of high-dose finasteride (5\u00a0mg\/day) versus low-dose finasteride (2.5\u00a0mg\/day) in the treatment of hirsutism. Eur J Endocrinol 147(4):467\u2013471. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12370107"},{"issue":"3","key":"4996_CR59","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.fertnstert.2004.02.118","volume":"82","author":"M Tartagni","year":"2004","unstructured":"Tartagni M, Schonauer MM, Cicinelli E et al (2004) Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil Steril 82(3):752\u2013755. https:\/\/doi.org\/10.1016\/j.fertnstert.2004.02.118","journal-title":"Fertil Steril"},{"key":"4996_CR60","doi-asserted-by":"crossref","unstructured":"Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR (1999) Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 71(3):445\u2013451. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10065780","DOI":"10.1097\/00006254-199907000-00020"},{"issue":"1","key":"4996_CR61","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1210\/jcem.85.1.6245","volume":"85","author":"P Moghetti","year":"2000","unstructured":"Moghetti P, Tosi F, Tosti A et al (2000) Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 85(1):89\u201394. https:\/\/doi.org\/10.1210\/jcem.85.1.6245","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4996_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijgo.2004.06.003","volume":"87","author":"A Beigi","year":"2004","unstructured":"Beigi A, Sobhi A, Zarrinkoub F (2004) Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Int J Gynaecol Obstet 87(1):29\u201333. https:\/\/doi.org\/10.1016\/j.ijgo.2004.06.003","journal-title":"Int J Gynaecol Obstet"},{"issue":"10","key":"4996_CR63","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/BF03350800","volume":"21","author":"E Faloia","year":"1998","unstructured":"Faloia E, Filipponi S, Mancini V, Di Marco S, Mantero F (1998) Effect of finasteride in idiopathic hirsutism. J Endocrinol Investig 21(10):694\u2013698. https:\/\/doi.org\/10.1007\/BF03350800","journal-title":"J Endocrinol Investig"},{"issue":"6","key":"4996_CR64","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/BF03350769","volume":"21","author":"Y Sahin","year":"1998","unstructured":"Sahin Y, Bayram F, Kelestimur F, Muderris I (1998) Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Investig 21(6):348\u2013352. https:\/\/doi.org\/10.1007\/BF03350769","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"4996_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0029-1212097","volume":"107","author":"F Bayram","year":"1999","unstructured":"Bayram F, Muderris II, Sahin Y, Kelestimur F (1999) Finasteride treatment for one year in 35 hirsute patients. Exp Clin Endocrinol Diabetes 107(3):195\u2013197. https:\/\/doi.org\/10.1055\/s-0029-1212097","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"4996_CR66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/09513590312331290328","volume":"17","author":"F Bayram","year":"2003","unstructured":"Bayram F, M\u00fcderris I, G\u00fcven M, Oz\u00e7elik B, Kele\u015ftimur F (2003) Low-dose (2.5\u00a0mg\/day) finasteride treatment in hirsutism. Gynecol Endocrinol 17(5):419\u2013422","journal-title":"Gynecol Endocrinol"},{"key":"4996_CR67","unstructured":"Muderris II, Bayram F, Guven M (2000) A prospective, randomized trial comparing flutamide (250\u00a0mg\/day) and finasteride (5\u00a0mg\/day) in the treatment of hirsutism. Fertil Steril 73(5):984\u2013987. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10785225"},{"key":"4996_CR68","doi-asserted-by":"crossref","unstructured":"Lakryc EM, Motta EL, Soares Jr JM, Haidar MA, de Lima GR, Baracat EC (2003) The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol 17(1):57\u201363. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12724020","DOI":"10.1080\/gye.17.1.57.63"},{"key":"4996_CR69","doi-asserted-by":"crossref","unstructured":"Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G (1999) Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 141(4):361\u2013367. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10526249","DOI":"10.1530\/eje.0.1410361"},{"issue":"6","key":"4996_CR70","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","volume":"55","author":"EA Olsen","year":"2006","unstructured":"Olsen EA, Hordinsky M, Whiting D et al (2006) The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 55(6):1014\u20131023. https:\/\/doi.org\/10.1016\/j.jaad.2006.05.007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4996_CR71","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","volume":"60","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60(3):434\u2013441","journal-title":"Urology"},{"issue":"4","key":"4996_CR72","first-page":"550","volume":"41","author":"L Drake","year":"1999","unstructured":"Drake L, Hordinsky M, Fiedler V et al (1999) The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 41(4):550\u2013554","journal-title":"J Am Acad Dermatol"},{"key":"4996_CR73","doi-asserted-by":"crossref","unstructured":"Chau CH, Price DK, Till C et al (2015) Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial. PLoS ONE 10(5):e0126672. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25955319","DOI":"10.1371\/journal.pone.0126672"},{"issue":"11","key":"4996_CR74","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s10552-014-0455-6","volume":"25","author":"RG Duijnhoven","year":"2014","unstructured":"Duijnhoven RG, Straus SM, Souverein PC et al (2014) Long-term use of 5alpha-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control 25(11):1577\u20131582. https:\/\/doi.org\/10.1007\/s10552-014-0455-6 . Epub 19 Aug 2014","journal-title":"Cancer Causes Control"},{"issue":"5","key":"4996_CR75","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.juro.2013.04.132","volume":"190","author":"ST Bird","year":"2013","unstructured":"Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M (2013) Male breast cancer and 5alpha-reductase inhibitors finasteride and dutasteride. J Urol 190(5):1811\u20131814. https:\/\/doi.org\/10.1016\/j.juro.2013.04.132 . Epub 9 May 2013","journal-title":"J Urol"},{"issue":"1","key":"4996_CR76","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cam4.1273","volume":"7","author":"M Meijer","year":"2018","unstructured":"Meijer M, Thygesen LC, Green A et al (2018) Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. Cancer Med 7(1):254\u2013260. https:\/\/doi.org\/10.1002\/cam4.1273","journal-title":"Cancer Med"},{"issue":"4","key":"4996_CR77","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D et al (1989) Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 29(4):342\u2013347","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4996_CR78","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/cncr.11663","volume":"98","author":"CI Li","year":"2003","unstructured":"Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen K, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65\u201379\u00a0years. Cancer 98(7):1504\u20131513. https:\/\/doi.org\/10.1002\/cncr.11663","journal-title":"Cancer"},{"key":"4996_CR79","doi-asserted-by":"publisher","unstructured":"Fryzek JP, Poulsen AH, Lipworth L et al (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 97(3):231\u2013236. https:\/\/doi.org\/10.1007\/s10549-005-9091-x . Accessed 24 March 2018","DOI":"10.1007\/s10549-005-9091-x"},{"issue":"6","key":"4996_CR80","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","volume":"37","author":"RJ Biggar","year":"2013","unstructured":"Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M (2013) Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol 37(6):870\u2013875. https:\/\/doi.org\/10.1016\/j.canep.2013.10.004 . Epub 1 Nov 2013","journal-title":"Cancer Epidemiol"},{"key":"4996_CR81","doi-asserted-by":"publisher","first-page":"e4447","DOI":"10.1136\/bmj.e4447","volume":"345","author":"IS Mackenzie","year":"2012","unstructured":"Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L (2012) Spironolactone and risk of incident breast cancer in women older than 55\u00a0years: retrospective, matched cohort study. BMJ 345:e4447","journal-title":"BMJ"},{"key":"4996_CR82","doi-asserted-by":"publisher","unstructured":"Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM (2017) Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 83(3):653\u2013663. https:\/\/doi.org\/10.1111\/bcp.13152 . Accessed 17 March 2018","DOI":"10.1111\/bcp.13152"},{"key":"4996_CR83","unstructured":"Ober KP, Hennessy JF (1978) Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann Intern Med 89(5):643\u2013644. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/717935"},{"issue":"9","key":"4996_CR84","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1210\/jc.2013-1040","volume":"98","author":"MA Ganie","year":"2013","unstructured":"Ganie MA, Khurana ML, Nisar S et al (2013) Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab 98(9):3599\u20133607. https:\/\/doi.org\/10.1210\/jc.2013-1040 . Epub 11 July 2013","journal-title":"J Clin Endocrinol Metab"},{"key":"4996_CR85","doi-asserted-by":"crossref","unstructured":"Boisselle A, Tremblay RR (1979) New therapeutic approach to the hirsute patient. Fertil Steril 32(3):276\u2013279. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/488407","DOI":"10.1016\/S0015-0282(16)44232-9"},{"key":"4996_CR86","doi-asserted-by":"crossref","unstructured":"Cumming DC, Yang JC, Rebar RW, Yen SS (1982) Treatment of hirsutism with spironolactone. JAMA 247(9):1295\u20131298. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7199587","DOI":"10.1001\/jama.1982.03320340049034"},{"key":"4996_CR87","unstructured":"Milewicz A, Silber D, Kirschner MA (1983) Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol 61(4):429\u2013432. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6828272"},{"key":"4996_CR88","doi-asserted-by":"crossref","unstructured":"Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R (1985) The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 43(2):200\u2013205. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3967781","DOI":"10.1016\/S0015-0282(16)48373-1"},{"issue":"3","key":"4996_CR89","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1210\/jcem-51-3-429","volume":"51","author":"G Shapiro","year":"1980","unstructured":"Shapiro G, Evron S (1980) A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab 51(3):429\u2013432. https:\/\/doi.org\/10.1210\/jcem-51-3-429","journal-title":"J Clin Endocrinol Metab"},{"key":"4996_CR90","doi-asserted-by":"crossref","unstructured":"Dorrington-Ward P, McCartney AC, Holland S et al (1985) The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol (Oxf) 23(2):161\u2013167. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4053414","DOI":"10.1111\/j.1365-2265.1985.tb00211.x"},{"key":"4996_CR91","doi-asserted-by":"crossref","unstructured":"Smals AG, Kloppenborg PW, Hoefnagels WH, Drayer JI (1979) Pituitary\u2013thyroid function in spironolactone treated hypertensive women. Acta Endocrinol 90(4):577\u2013584. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/107696","DOI":"10.1530\/acta.0.0900577"},{"key":"4996_CR92","doi-asserted-by":"crossref","unstructured":"Siegberg R, Ylostalo P, Laatikainen T, Pelkonen R, Stenman UH (1987) Endocrine and clinical effects of spironolactone in female hyperandrogenism. Arch Gynecol 240(2):67\u201373. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3566358","DOI":"10.1007\/BF02134038"},{"key":"4996_CR93","doi-asserted-by":"crossref","unstructured":"Erenus M, Yucelten D, Durmusoglu F, Gurbuz O (1997) Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril 68(6):1000\u20131003. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9418687","DOI":"10.1016\/S0015-0282(97)00371-3"},{"key":"4996_CR94","doi-asserted-by":"crossref","unstructured":"Spritzer PM, Lisboa KO, Mattiello S, Lhullier F (2000) Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 52(5):587\u2013594. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10792338","DOI":"10.1046\/j.1365-2265.2000.00982.x"},{"key":"4996_CR95","unstructured":"Sert M, Tetiker T, Kirim S (2003) Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. Acta Med Okayama 57(2):73\u201376. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12866746"},{"key":"4996_CR96","doi-asserted-by":"crossref","unstructured":"Lumachi F, Rondinone R (2003) Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 79(4):942\u2013946. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12749435","DOI":"10.1016\/S0015-0282(02)04927-0"},{"key":"4996_CR97","doi-asserted-by":"crossref","unstructured":"Kelestimur F, Everest H, Unluhizarci K, Bayram F, Sahin Y (2004) A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 150(3):351\u2013354. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15012621","DOI":"10.1530\/eje.0.1500351"},{"issue":"2","key":"4996_CR98","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-3083.2005.01072.x","volume":"19","author":"A Yemisci","year":"2005","unstructured":"Yemisci A, Gorgulu A, Piskin S (2005) Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 19(2):163\u2013166. https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01072.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4996_CR99","unstructured":"Some thyrotropic agents (2001) IARC monographs on the evaluation of carcinogenic risks to humans, No. 79, p 725"},{"issue":"1","key":"4996_CR100","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","volume":"35","author":"M Duvic","year":"1996","unstructured":"Duvic M, Lemak NA, Valero V et al (1996) A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35(1):74\u201378. https:\/\/doi.org\/10.1016\/S0190-9622(96)90500-9","journal-title":"J Am Acad Dermatol"},{"key":"4996_CR101","doi-asserted-by":"crossref","unstructured":"Rodriguez R, Machiavelli M, Leone B et al (1994) Minoxidil (mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol 5(8):769\u2013770. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7826913","DOI":"10.1093\/oxfordjournals.annonc.a058986"},{"issue":"3 Pt 2","key":"4996_CR102","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0190-9622(87)70084-X","volume":"16","author":"H Uno","year":"1987","unstructured":"Uno H, Cappas A, Brigham P (1987) Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 16(3 Pt 2):657\u2013668","journal-title":"J Am Acad Dermatol"},{"key":"4996_CR103","doi-asserted-by":"publisher","unstructured":"Hsu C, Liu J, Lin A, Yang C, Chung W, Wu W (2014) Minoxidil may suppress androgen receptor-related functions. OncoTarget 5(8):2187\u20132197. https:\/\/doi.org\/10.18632\/oncotarget.1886 . Accessed 7 April 2018","DOI":"10.18632\/oncotarget.1886"},{"issue":"3","key":"4996_CR104","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/1523-1747.ep12277095","volume":"92","author":"AE Buhl","year":"1989","unstructured":"Buhl AE, Waldon DJ, Kawabe TT, Holland JM (1989) Minoxidil stimulates mouse vibrissae follicles in organ culture. J Investig Dermatol 92(3):315\u2013320","journal-title":"J Investig Dermatol"},{"issue":"5","key":"4996_CR105","doi-asserted-by":"publisher","first-page":"74S","DOI":"10.1111\/1523-1747.ep12471911","volume":"96","author":"AE Buhl","year":"1991","unstructured":"Buhl AE (1991) Minoxidil\u2019s action in hair follicles. J Investig Dermatol 96(5):74S","journal-title":"J Investig Dermatol"},{"key":"4996_CR106","unstructured":"Burke BM, Cunliffe WJ (1985) Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 112(1):124\u2013125. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3155956"},{"issue":"3","key":"4996_CR107","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.det.2010.03.011","volume":"28","author":"D Rathnayake","year":"2010","unstructured":"Rathnayake D, Sinclair R (2010) Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 28(3):611\u2013618. https:\/\/doi.org\/10.1016\/j.det.2010.03.011","journal-title":"Dermatol Clin"},{"key":"4996_CR108","unstructured":"Sawaya ME, Price VH (1997) Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Investig Dermatol 109(3):296\u2013300. Accessed 19 March 2018"},{"key":"4996_CR109","doi-asserted-by":"crossref","unstructured":"Tolino A, Petrone A, Sarnacchiaro F et al (1996) Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 66(1):61\u201365. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8752612","DOI":"10.1097\/00006254-199611000-00019"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-4996-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T11:05:18Z","timestamp":1694084718000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-4996-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4996"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4996-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"30 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest with regard to the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Mario E. Lacouture has no relevant conflicts of interest with regard to preparation of this manuscript. He has served as consultant for Legacy, Adgero, Debiopharm,Galderma, Johnson and Johnson, Novocure Inc., Merck, Helsinn, Janssen, Menlo Ther, Novartis, Roche, Abbvie,\u00a0Boehringer Ingelheim,\u00a0Amgen,\u00a0E.R. Squibb & Sons,\u00a0EMD Serono,\u00a0Genentech, Seattle Genetics, Bayer, Manner SAS,\u00a0\u00a0Lutris,\u00a0Paxman Coolers,\u00a0Pfizer, Bristol-Myers Squibb, Silk Therapeutics, Foamix, and Medische Voet. He has received research funding from GSK, Novartis,\u00a0Veloce,\u00a0US Biotest, Berg, Bristol-Myers Squibb.\u00a0Eliza B. Geer has no relevant conflicts\u00a0of interest with regard to preparation of this manuscript. She has served as the principal investigator of research grants to MSKCC from Novartis, Strongbridge, Chiasma, and IONIS and has received occasional consulting honoraria from Novartis, Strongbridge, Corcept, and Pfizer. Jerry Shapiro has no relevant conflicts of interest with regard to preparation of this manuscript. He has served as a consultant for\u00a0Aclaris, Samumed, Incyte, Replicel Life Sciences, and\u00a0Shook, Hardy, Bacon LLP who represent Sanofi Aventis US LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}